Clairity receives FDA OK for breast cancer risk prediction tool
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter.
The Food and Drug Administration has authorized the first artificial intelligence tool to predict patients' five-year breast cancer risk from a routine mammogram.
Boston-based startup Clairity developed the tool, called Clairity Breast. The company plans to launch the risk assessment feature by the end of the year, according to a Monday announcement.
'We're doing something radically different than what I've done my whole career in the area of computer-aided detection and diagnosis of breast cancer,' Connie Lehman, founder of Clairity and a diagnostic radiologist at Mass General Brigham, said in an interview.
AI has been used to detect breast cancer for decades; the first computer-aided detection system for breast cancer was approved in 1998, Lehman said. However, most of these tools are used to detect cancer, not predict future risk.
'What we're doing here is doing something humans can't do,' Lehman said. 'It's extracting subtle cues in the mammogram that the human eye can't see, the human brain can't process.'
About 2.3 million new cases of breast cancer were diagnosed worldwide in 2022, according to the latest data from the World Health Organization. Current risk models factor in age and family history, but most people diagnosed have no family history.
Lehman, who has focused most of her career on better ways to detect breast cancer early, expects the new approach will 'expand the net out to more women who truly are at high risk, and until now we haven't been able to identify.'
Clairity Breast was developed using Hologic's 2D screening mammography systems. It would be used as part of a patient's routine mammogram.
The company was careful to train its AI models on a diverse group of patients, Lehman said, as historically, breast cancer risk prediction models were built on data from predominantly white women.
Clairity plans to launch the predictive tool starting with select centers and expanding access later this year, Lehman said. The company last year hired Jeffrey Luber as CEO to help lead the market launch. Luber is the former CEO of testing firms Binx Health and Exact Sciences.
Clairity received a $1 million investment from the Breast Cancer Research Foundation in January.
Recommended Reading
Nvidia's David Niewolny on the future of AI in medical devices
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Palantir CEO Warns of AI Arms Race With China
Palantir (PLTR, Financials) CEO Alex Karp said Thursday that artificial intelligence poses serious risks and that the ongoing AI arms race will ultimately be won by either the United States or China. There are positive and negative consequences, and either we win or China will win, Karp told CNBC's Squawk on the Street. He emphasized that the U.S. currently holds an advantage due to corporate willingness to embrace new technologies, but said Western allies, particularly in Europe, are lagging behind and must learn from the U.S. approach. In the interview, Karp also addressed a recent New York Times report suggesting Palantir is assisting the Trump administration in gathering data on American citizens. He denied the claim, stating, We are not surveilling Americans. The Denver-based data analytics and AI software firm has gained 74% year to date as investors bet on the company's growing role in U.S. government contracts and defense applications. While the stock continues to outperform broader tech peers, Karp acknowledged investor concerns around its valuation. You don't like the price, exit, he said. This article first appeared on GuruFocus.
Yahoo
36 minutes ago
- Yahoo
You.com seeking $1.4bn valuation in new funding round
AI startup is in discussions to secure new funding at a valuation of $1.4bn, The Information reported. The Palo Alto-based startup, which focuses on AI search for business, plans to use the funds to bolster its AI assistant offerings. This development follows its shift from general-purpose AI search to work-related task assistance. The talks come after $50m Series B round in 2024, which included investments from Day One Ventures, DuckDuckGo, Gen Digital, Georgian, NVIDIA, Salesforce Ventures and SBVA. This round increased its total funding to $99m, elevating its valuation to between $700m and $900m. gained attention with the launch of ChatGPT in late 2022, capitalising on the interest in AI-powered search. However, interest waned as competitors such as Microsoft's AI-infused Bing and Google's advanced search responses gained traction. In response, repositioned itself as an AI assistant to enhance productivity while maintaining internet search capabilities. Founded in 2020 by former Salesforce AI leads Richard Socher and Bryan McCann, now highlights its ability to summarise information, answer questions, and support daily workflows. Richard Socher, CEO and chief scientist, said that the platform can generate text, write code, and interact with various tools for precise results, though he did not comment on the current fundraising plans. offers a premium plan at $15 per month (billed annually), providing access to AI models and productivity features, slightly undercutting competitors like Google, Microsoft, and OpenAI, which charge $20 monthly. In addition to its consumer-facing AI assistant, is expanding into the enterprise market. The company provides a suite of AI tools, including agents and APIs, to help organisations enhance employee productivity and explore new revenue opportunities. " seeking $1.4bn valuation in new funding round" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
44 minutes ago
- Yahoo
Alzheimer's blood test can accurately pick up early symptoms
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. "This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting," he added. "While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed."
